Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit

Published: Tuesday, September 24, 2013
Last Updated: Tuesday, September 24, 2013
Bookmark and Share
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.

Luminex Corporation has announced that it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit.

This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene.

"Since cytochrome [CYP450] enzymes are responsible for metabolizing over half of all drugs on the market today, it is important for a physician to have valuable information to determine whether a patient's specific genotype may impact their drug response," said Patrick J. Balthrop, president and chief executive officer of Luminex.

Balthrop continued, "Our growing portfolio of pharmacogenetic assays include both FDA cleared and CE marked xTAG CYP2D6 and CYP2C19 assays demonstrating our commitment to offer testing laboratories regulatory cleared assays that are safe and effective for use as an aid in patient management decisions."

Cytochrome P450 2C19 (CYP2C19) is a clinically important gene that encodes a phase one drug metabolizing enzyme.

The CYP2C19 enzyme is responsible for metabolizing a variety of prodrugs and drugs used to treat a number of conditions such as ulcers, seizures, malaria and anxiety. It is also important in metabolizing drugs such as beta-blockers, anti-clotting agents and some antidepressants.

Genetic variations in the CYP2C19 gene can result in distinct drug metabolizing phenotypes leading to sub-optimal drug responses, such as drug toxicity, adverse drug reactions (ADRs), or inadequate therapeutic effect.

The FDA Adverse Events Reporting system (FAERS) estimated nearly 800,000 ADRs in the U.S. and Europe combined for the year 2011.

The incidence of serious and fatal ADRs has been rising with the increase in the number of medications prescribed.

An estimated $3.5 billion is spent on additional medical cost associated with ADRs annually and at least 40% of ambulatory ADRs may be preventable.

Luminex's xTAG CYP2C19 Kit is an IVD assay that analyzes a patient's CYP2C19 genotype from genomic DNA extracted from EDTA or citrate anticoagulated whole blood samples to aid clinicians in determining therapeutic strategy for therapeutics metabolized by the cytochrome P450 2C19 gene product.

The assay is run on the versatile Luminex® 100/200™ or MAGPIX® instruments.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Zika Test Granted FDA Emergency Use Authorization
The test is designed to detect zika virus RNA in potentially infected patients using their blood serum, plasma, or urine.
Tuesday, August 09, 2016
Luminex Corporation Receives FDA Clearance
Company has received FDA clearance for new molecular test for identification and differentiation of influenza A/B and respiratory syncytial virus.
Thursday, August 04, 2016
Luminex Receives FDA Clearance for Aries M1 System
Company has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System.
Thursday, July 07, 2016
Luminex Completes Acquisition of Nanosphere
The acquisition provides Luminex with Nanosphere's high-plex, low-throughput system to complement its existing molecular platforms.
Friday, July 01, 2016
Luminex Receives CE-IVD Mark
Company has announced that it has received CE-IVD mark for ARIES® Flu A/B & RSV Assay.
Thursday, June 02, 2016
Luminex to Acquire Nanosphere
Nanosphere to be acquired for $1.35 per share in an all cash transaction valued at approximately $58 million.
Monday, May 16, 2016
Luminex SYNCT Software Receives FDA Clearance, CE Mark
Company has announced that its SYNCT™ Software has received both U.S. FDA clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System.
Friday, April 15, 2016
Luminex Receives CE-IVD Mark for ARIES System
The ARIES® System and ARIES®HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Tuesday, March 22, 2016
Luminex, University of Sao Paulo Collaborate
Luminex Corporation has announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner,GenArraytion, Inc.
Monday, February 29, 2016
Luminex Corporation Announces Collaboration with University of Sao Paulo
Company has announced collaboration to validate a multi analyte zika virus detection panel for detect multiple disease agent.
Friday, February 26, 2016
Luminex Corporation Receives Medical Device License
Company has announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate for ARIES System and ARIES HSV 1&2 Assay.
Tuesday, February 23, 2016
Luminex and Bio-Techne Extend and Expand Partnership
Company expands global distribution of award-winning multiplexing instrumentation.
Friday, October 23, 2015
Luminex Receives FDA Clearance
Company has received clearance for ARIES® System and ARIES® HSV 1&2 Assay.
Thursday, October 08, 2015
Luminex Corporation Reports Second Quarter 2013 Results
Achieves milestone selling 10,000th multiplexing analyzer.
Tuesday, July 30, 2013
Luminex Receives FDA and European Clearance for New Version of xTAG® CYP2D6 Kit
Luminex submits xTAG® CYP2C19 kit to FDA for review.
Tuesday, July 16, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!